Best Telehealth for ADHD: Online Assessment and Treatment

Getting an ADHD diagnosis used to mean a months-long wait for a specialist, a battery of in-office neuropsychological tests costing an estimated $1,000 to $3,000, and weeks of uncertainty. Telehealth has compressed that timeline for many people, with some platforms offering assessments in under a week. But finding the best telehealth for ADHD is less about speed than about quality and safety: which services conduct a genuine, comprehensive evaluation, how controlled-substance prescribing rules apply under evolving DEA and HHS regulations, and how to avoid operators that treat stimulant prescriptions like a subscription product. An estimated 8 to 9 million U.S. adults have ADHD according to the National Institute of Mental Health, and many were diagnosed in adulthood. For background on how telehealth works across conditions, start with our comprehensive telehealth guide. This article is educational information, not medical advice; diagnosis and treatment must be directed by a qualified clinician, and no medication dosing is provided here.

How ADHD Telehealth Works

ADHD telehealth typically involves three phases: assessment, diagnosis, and ongoing treatment. Understanding each phase helps you evaluate whether a platform’s approach is thorough enough to produce an accurate diagnosis.

Assessment: A licensed clinician (usually a psychiatrist, psychiatric nurse practitioner, or psychologist) conducts a comprehensive video interview, commonly lasting 45 to 90 minutes. They review standardized symptom questionnaires, such as the Adult ADHD Self-Report Scale (ASRS) or the Conners Adult ADHD Rating Scale. The interview explores your symptom history across different settings (work, home, relationships), childhood symptoms (ADHD is a neurodevelopmental condition that begins in childhood, even if not diagnosed until adulthood), and screens for conditions that mimic or co-occur with ADHD, including anxiety, depression, sleep disorders, substance use, and thyroid dysfunction.

Diagnosis: If the provider determines that you meet the DSM-5-TR criteria for ADHD — including several symptoms of inattention and/or hyperactivity-impulsivity present before age 12, with evidence of impairment in two or more settings — they may make a formal diagnosis. Not everyone who seeks an evaluation has ADHD; a quality provider will rule out other explanations for your symptoms before diagnosing, and will tell you if ADHD is not the best explanation.

Treatment: Treatment options are chosen and directed by your clinician and typically include stimulant medications (methylphenidate- and amphetamine-based products), non-stimulant medications (atomoxetine, guanfacine, viloxazine), behavioral strategies, and ADHD coaching. Many platforms also offer therapy alongside medication management. Ongoing treatment involves periodic follow-up visits to assess how treatment is working, adjust the plan, and monitor side effects. These follow-ups are well-suited to telehealth, as they involve conversation rather than physical examination. This article does not provide dosing; that is determined by your prescriber.

What Good ADHD Telehealth Looks Like (and What to Avoid)

Because the field grew quickly, it now includes both careful, clinically rigorous services and questionable operators. Rather than ranking “top platforms,” it is more useful to judge any service against the standard of care. Two high-profile cautionary tales illustrate why.

In 2024, the U.S. Department of Justice brought criminal charges against the founders of Done Global (Done), alleging a scheme to distribute Adderall and other stimulants through telehealth — reported as one of the first federal criminal drug-distribution prosecutions of a digital telehealth company. Separately, Cerebral came under DEA and DOJ scrutiny over its controlled-substance prescribing practices and reached a federal settlement resolving alleged Controlled Substances Act violations, after earlier restructuring how it handled stimulants. These cases do not mean telehealth ADHD care is illegitimate — they mean the evaluation and prescribing practices behind a platform matter enormously, and marketing built around fast, easy stimulant access is a serious warning sign. Because platforms, ownership, business models, and even whether a given service still operates can change quickly, verify a service’s current standing and clinician credentials yourself before enrolling; do not rely on any single “best of” list, including older versions of this one.

Whatever service you consider, insist on the following: licensed clinicians with verifiable credentials; a comprehensive evaluation (not a brief questionnaire); screening for co-occurring conditions; a prescriber who is willing to say no or recommend non-medication approaches; transparent pricing; and clear, easy cancellation. Treatment decisions, including whether any medication is appropriate, belong with your clinician.

Types of ADHD Telehealth Services

Dedicated ADHD platforms

Several companies focus specifically on ADHD evaluation and medication management, often advertising initial assessments in the range of an estimated $150 to $250 and monthly follow-ups around $75 to $120, with some accepting insurance. Their appeal is speed and focus. The trade-off is that a narrow, high-volume model can create pressure toward quick prescriptions, which is exactly what regulators have scrutinized. If you use one, confirm that the evaluation is genuinely comprehensive, that the clinician is licensed in your state, and that the service is not marketing stimulant access as its selling point. Prices and the roster of active services change frequently, so verify current details directly.

Broad mental-health platforms with therapy

Some telehealth companies offer ADHD care within a broader mental-health service that also provides therapy, which can be valuable because ADHD frequently co-occurs with anxiety, depression, or sleep problems. Combined medication-and-therapy plans are typically more expensive — often an estimated $250 to $350 per month cash-pay — but having a prescriber and therapist coordinating care is a genuine strength for people who need both. Following regulatory scrutiny across the industry, several of these platforms adopted more conservative, thorough prescribing practices, sometimes starting with non-stimulant options or non-medication approaches when clinically appropriate.

Assessment-focused and testing-oriented services

A few services emphasize a more in-depth diagnostic assessment, sometimes adding computerized attention testing (such as a continuous performance test) reviewed by a licensed psychologist, with a written report. No single computerized test can diagnose ADHD on its own — diagnosis is clinical — but a rigorous assessment and a detailed report can add diagnostic confidence and provide useful documentation for workplace accommodations, academic support, or insurance appeals. These services suit people who want a thorough first-time evaluation.

Insurance-based psychiatry

Major insurers, including UnitedHealthcare, Aetna, and Cigna, cover psychiatry and ADHD treatment through telehealth. Copays commonly run an estimated $20 to $75 per session, which can make ongoing treatment significantly cheaper than dedicated cash-pay platforms if your plan has favorable behavioral-health benefits. The trade-offs are longer waits for an initial evaluation (often several weeks) and providers who may be generalists rather than ADHD specialists. For many people, this is the most sustainable and clinically sound option, and it is usually worth checking first.

The DEA Factor: Stimulant Prescribing Rules

Any discussion of ADHD telehealth must address the regulatory landscape, because it directly affects whether and how you can receive a stimulant prescription remotely. The commonly prescribed stimulants (such as Adderall, Ritalin, Vyvanse, Concerta, and Focalin) are Schedule II controlled substances — among the most tightly regulated medications in the United States.

During the COVID-19 public health emergency, the DEA and HHS temporarily relaxed the usual requirement for an in-person visit before a controlled substance could be prescribed via telehealth. Since then, those flexibilities have been repeatedly extended while the agencies work to finalize permanent rules (including a proposed “special registration” framework for telemedicine prescribing). Because the rules have shifted through multiple cycles and continued to be revised beyond the time of writing, you should treat any specific requirement as subject to change and verify the current rules before relying on telehealth for a stimulant prescription. In practice, depending on the rules in force and your clinician’s judgment, you may be able to start via telehealth but be required to complete an in-person evaluation within a defined period to continue. Your prescriber and pharmacy can tell you what currently applies to your situation.

Non-stimulant medications — such as atomoxetine (Strattera), guanfacine (Intuniv), viloxazine (Qelbree), and clonidine (Kapvay) — are not controlled substances and are generally not subject to these telehealth restrictions. Some patients and clinicians choose to start with a non-stimulant option, both for clinical reasons (for example, co-occurring anxiety, or a wish to avoid a medication with misuse potential) and to sidestep the regulatory uncertainty around stimulants. Stimulants are often more effective for core ADHD symptoms, but non-stimulants work well for many people. Which medication, if any, is appropriate is a decision for your clinician, not a platform’s marketing.

The regulatory concern is not that telehealth ADHD care is inherently problematic. It is that inadequate evaluations can lead to inappropriate prescribing, misuse, and diversion of controlled substances. Services that conduct thorough assessments and follow evidence-based prescribing practices are best positioned to operate responsibly within whatever framework is in force.

Cost Comparison

ADHD treatment costs vary significantly by service and insurance status. The figures below are estimates as of early 2026 and change frequently — verify current pricing before enrolling. This is cost information, not medication guidance.

• Initial evaluation (dedicated platforms, cash pay): an estimated $150 to $250
• Monthly medication management (dedicated platforms): an estimated $75 to $120/month
• Comprehensive platforms with therapy: an estimated $250 to $350/month for combined medication and therapy
• Insurance-based telehealth: an estimated $20 to $75 per session (plus the initial evaluation copay)
• Medication costs with insurance: generic stimulants often $10 to $40/month; brand-name can be much higher, depending on your plan’s formulary
• Medication costs without insurance: many generic stimulants fall in the tens of dollars per month, while brand-name products can run into the hundreds; manufacturer copay cards or pharmacy discount programs may reduce this. Actual prices vary by pharmacy and product.
• Non-stimulant medication costs: several generics are relatively inexpensive, though newer brand-name non-stimulants cost more

For patients on high-deductible plans who have not met their deductible, cash-pay platforms may be cheaper than using insurance for the provider visits. However, insurance pharmacy benefits typically provide better medication pricing than cash pay, especially for brand-name medications. The math depends on your specific plan, deductible status, and medication. See our deductible vs. out-of-pocket maximum guide for help with this calculation.

Red Flags to Watch For

The rapid growth of ADHD telehealth attracted both legitimate providers and questionable operators, and — as the federal cases above show — the difference is not merely academic. A poor evaluation can lead to misdiagnosis (either missing ADHD or incorrectly diagnosing it), inappropriate treatment, misuse or diversion of controlled substances, and regulatory problems that could interrupt your care. Be cautious of any service that:

• Guarantees a diagnosis before your evaluation (a legitimate provider cannot know the outcome in advance)
• Promises stimulant prescriptions up front or uses stimulant access as a marketing hook
• Does not conduct a thorough assessment, relying on a brief questionnaire and a short video chat
• Does not screen for co-occurring conditions (anxiety, depression, sleep disorders, substance use) that affect diagnosis and treatment
• Uses clinicians whose licensure or credentials you cannot verify, or who are not licensed in your state
• Charges excessively for services that should be straightforward, locks you into long-term contracts, or makes cancellation difficult

A legitimate ADHD evaluation should involve a detailed clinical interview lasting at least 30 to 45 minutes, standardized symptom rating scales, review of symptom history across settings (work, home, relationships), exploration of childhood symptoms, screening for co-occurring conditions, and a clear explanation of treatment options including non-medication approaches. It should also include an honest possibility that the answer is “this is not ADHD.”

Frequently Asked Questions

Can a telehealth doctor diagnose ADHD?

Yes. Licensed psychiatrists, psychologists, and psychiatric nurse practitioners can diagnose ADHD through telehealth using clinical interviews and validated assessment tools, and the American Psychiatric Association recognizes telepsychiatry as an appropriate modality. The key factor is the thoroughness of the evaluation and the qualifications of the clinician, not whether it happens on a screen or in an office.

Can I get a stimulant prescription like Adderall through telehealth?

Sometimes, but it depends on current DEA/HHS rules and your clinician’s judgment. These medications are Schedule II controlled substances, and the telehealth prescribing rules have been repeatedly extended and are still being finalized; depending on what is in force, an in-person evaluation may be required within a defined period. Non-stimulant alternatives are generally not subject to the same restrictions. Verify the current requirements with your prescriber and pharmacy. This article does not provide dosing.

What non-stimulant options exist for ADHD?

Non-stimulant medications used for ADHD include atomoxetine, viloxazine, guanfacine, and clonidine, and they are not controlled substances. They can be effective for many people, particularly those with co-occurring anxiety or a reason to avoid stimulants. Whether any medication is appropriate, and which one, is a clinical decision made with your prescriber — not something to select from a menu.

How long does an online ADHD assessment take?

Most telehealth ADHD evaluations take about 45 to 90 minutes, including the clinical interview and review of symptom questionnaires. Some assessment-focused services add computerized attention testing. Be skeptical of any “evaluation” that takes only a few minutes; a rushed assessment is a red flag.

Is online ADHD treatment as effective as in-person?

For medication management, research generally suggests telehealth follow-up can produce outcomes comparable to in-person care, because these visits are primarily conversational (discussing symptom control, side effects, and how the plan is working). Effectiveness depends on the quality of the evaluation and ongoing monitoring, not the medium alone.

What if I’ve been diagnosed with ADHD before but need a new provider?

If you have a prior diagnosis and existing medical records, many telehealth services can establish care more efficiently. Bring your previous diagnosis documentation, medication history, and any relevant records to your initial appointment. The new provider will review your history and, after an appropriate evaluation, may be able to continue an established treatment plan — subject to current controlled-substance rules for any stimulant.

What to Do Next

If you suspect you have ADHD, a sensible first step is to check whether your insurance covers telehealth psychiatric evaluations, since insurance-based care is often the cheapest and most clinically sound option for ongoing treatment even if the initial wait is longer. If cost or wait times are barriers, a reputable dedicated service can get you evaluated sooner — but choose it on the quality of its evaluation and the credentials of its clinicians, not on how quickly it promises a prescription. Be prepared for the possibility that treatment may involve non-medication strategies, a non-stimulant, or an eventual in-person visit under current regulations.

Getting a proper assessment is the critical first step, and it should be a real one. Untreated ADHD can affect work, relationships, finances, and quality of life, and many adults who receive an accurate diagnosis and appropriate, clinician-directed treatment report meaningful improvement. The goal is not simply to obtain a prescription quickly; it is to get an accurate diagnosis and a treatment plan that is right and safe for you.

Sources

• National Institute of Mental Health (NIMH) — ADHD in adults and prevalence data (nimh.nih.gov)
• American Psychiatric Association — DSM-5-TR ADHD criteria and telepsychiatry (psychiatry.org)
• DEA / HHS — telemedicine prescribing of controlled substances and temporary extensions of COVID-era flexibilities (deadiversion.usdoj.gov)
• U.S. Department of Justice — 2024 criminal charges against Done Global founders and the Cerebral controlled-substance settlement (justice.gov)
• CDC — ADHD data and treatment overview (cdc.gov)